INARI MEDICAL INC (NARI) Stock Price & Overview
NASDAQ:NARI • US45332Y1091
Current stock price
The current stock price of NARI is 79.97 USD. Today NARI is up by 0.05%. In the past month the price increased by 0.53%. In the past year, price increased by 40.08%.
NARI Key Statistics
- Market Cap
- 4.683B
- P/E
- N/A
- Fwd P/E
- 405.53
- EPS (TTM)
- -0.77
- Dividend Yield
- N/A
NARI Stock Performance
NARI Stock Chart
NARI Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to NARI. When comparing the yearly performance of all stocks, NARI is one of the better performing stocks in the market, outperforming 95.58% of all stocks.
NARI Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to NARI. The financial health of NARI is average, but there are quite some concerns on its profitability.
NARI Earnings
On October 28, 2024 NARI reported an EPS of -0.09 and a revenue of 153.39M. The company beat EPS expectations (31.16% surprise) and missed revenue expectations (-0.19% surprise).
NARI Forecast & Estimates
22 analysts have analysed NARI and the average price target is 76.99 USD. This implies a price decrease of -3.73% is expected in the next year compared to the current price of 79.97.
For the next year, analysts expect an EPS growth of -2492.94% and a revenue growth 22.24% for NARI
NARI Groups
Sector & Classification
NARI Financial Highlights
Over the last trailing twelve months NARI reported a non-GAAP Earnings per Share(EPS) of -0.77. The EPS decreased by -1183.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.27% | ||
| ROE | -18.07% | ||
| Debt/Equity | 0 |
NARI Ownership
NARI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 17.91 | 178.754B | ||
| ISRG | INTUITIVE SURGICAL INC | 44.23 | 160.562B | ||
| SYK | STRYKER CORP | 21.92 | 126.877B | ||
| BSX | BOSTON SCIENTIFIC CORP | 17.96 | 93.218B | ||
| EW | EDWARDS LIFESCIENCES CORP | 26.9 | 47.074B | ||
| IDXX | IDEXX LABORATORIES INC | 38.42 | 45.348B | ||
| BDX | BECTON DICKINSON AND CO | 11.33 | 43.995B | ||
| RMD | RESMED INC | 18.25 | 32.645B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 13.61 | 32.062B | ||
| DXCM | DEXCOM INC | 24.47 | 23.946B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.72 | 17.783B | ||
| HOLX | HOLOGIC INC | 15.41 | 16.888B | ||
| PODD | INSULET CORP | 31.6 | 14.383B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NARI
Company Profile
Inari Medical, Inc. operates as a medical device company. The company is headquartered in Irvine, California and currently employs 1,300 full-time employees. The company went IPO on 2020-05-22. The Company’s products primarily consist of ClotTriever and FlowTriever systems, which are catheter-based mechanical thrombectomy systems that are used for the treatment of the venous thromboembolism (VTE) deep vein thrombosis (DVT), and pulmonary embolism (PE). Its InThrill system is used for the removal of emboli and thrombi from the peripheral vasculature. The LimFlow system is indicated for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and are at risk of major amputation. The company also offers RevCore thrombectomy catheter, which is a thrombectomy device for venous stent thrombosis, Triever 16 Curve catheter, which is used for venous thrombus removal, and ClotTriever Bold catheter, which is used for DVT and the removal of acute and chronic clots in the peripheral vasculature. Its ClotTriever XL, which is a catheter for efficient clot removal with minimal blood loss.
Company Info
IPO: 2020-05-22
INARI MEDICAL INC
6001 Oak Canyon, Suite 100
Irvine CALIFORNIA 92618 US
CEO: William Hoffman
Employees: 1300
Phone: 19499234747
INARI MEDICAL INC / NARI FAQ
What does NARI do?
Inari Medical, Inc. operates as a medical device company. The company is headquartered in Irvine, California and currently employs 1,300 full-time employees. The company went IPO on 2020-05-22. The Company’s products primarily consist of ClotTriever and FlowTriever systems, which are catheter-based mechanical thrombectomy systems that are used for the treatment of the venous thromboembolism (VTE) deep vein thrombosis (DVT), and pulmonary embolism (PE). Its InThrill system is used for the removal of emboli and thrombi from the peripheral vasculature. The LimFlow system is indicated for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and are at risk of major amputation. The company also offers RevCore thrombectomy catheter, which is a thrombectomy device for venous stent thrombosis, Triever 16 Curve catheter, which is used for venous thrombus removal, and ClotTriever Bold catheter, which is used for DVT and the removal of acute and chronic clots in the peripheral vasculature. Its ClotTriever XL, which is a catheter for efficient clot removal with minimal blood loss.
What is the current price of NARI stock?
The current stock price of NARI is 79.97 USD. The price increased by 0.05% in the last trading session.
Does INARI MEDICAL INC pay dividends?
NARI does not pay a dividend.
What is the ChartMill technical and fundamental rating of NARI stock?
NARI has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the analyst forecast for NARI stock?
22 analysts have analysed NARI and the average price target is 76.99 USD. This implies a price decrease of -3.73% is expected in the next year compared to the current price of 79.97.
Can you provide the growth outlook for INARI MEDICAL INC?
The Revenue of INARI MEDICAL INC (NARI) is expected to grow by 22.24% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the next earnings date for NARI stock?
INARI MEDICAL INC (NARI) will report earnings on 2025-03-04, after the market close.